Jigar Shah, MD
Rheumatology · Margate, FLNPI 1659508166
Payments from drug & device makers
Across 1,791 payments — averaging $3105.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3.1M
- AbbVie$570K
- Eli Lilly$387K
- Sun Pharmaceutical Industries Inc.$349K
- Novartis$299K
- GSK$239K
- plus $578K from 43 others
Across 4 payments — averaging $7105.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$28K
What the payments were for
- Consulting fees$36,3355%
- Speaking & faculty fees$631,78484%
- Grants$2400%
- Travel & lodging$54,0037%
- Food & beverage$26,8644%
- Education$5140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,561,629 in reported general payments places this provider in the 95th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 61 | $427,628 |
| RinvoqUpadacitinib | 46 | $297,661 |
| Enbrel MiniEtanercept | 28 | $220,189 |
| RemicadeInfliximab | 26 | $176,591 |
| TymlosAbaloparatide | 50 | $140,420 |
| OrenciaAbatacept/Maltose | 31 | $134,781 |
| SaphneloAnifrolumab-Fnia | 20 | $103,498 |
| Enbrel SureclickEtanercept | 13 | $96,406 |
| Simponi AriaGolimumab | 13 | $83,409 |
| Taltz AutoinjectorIxekizumab | 12 | $81,657 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $67,528 |
| KevzaraSarilumab | 13 | $58,154 |
| ProliaDenosumab | 28 | $48,951 |
| ActemraTocilizumab | 27 | $48,247 |
| Hydroxychloroquine Sulfate | 234 | $6,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $569,933 | $297,66146 claims |
| Johnson & JohnsonRemicade, Simponi Aria | $1,913 | $260,00039 claims |
| Radius Health, Inc.Tymlos | $595 | $140,42050 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $200,079 | $134,78131 claims |
| AstraZenecaSaphnelo | $143,822 | $103,49820 claims |
| UCB, Inc.Cimzia (2 Pack) | $26,162 | $67,52812 claims |
| SanofiKevzara | $29,149 | $58,15413 claims |
| AmgenProlia | $3,138,743 | $48,95128 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $59 | $87623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Margate
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Guillermo ValenzuelaPlantation$14.2M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
- Benidecto FernandezHialeah$2.9M
- Norman GaylisAventura$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.